The USPTO has issued patent US12583887B2, covering novel compounds and agents for imaging prostate-specific membrane antigen (PSMA). The patent, assigned to Siemens Medical Solutions USA, Inc., includes methods for synthesizing these agents and for imaging PSMA, specifically noting suitability for PET and SPECT imaging. The patent's filing date was August 21, 2020, and it is set to grant on March 24, 2026.

This patent grant represents a new intellectual property asset for Siemens Medical Solutions USA, Inc. in the field of diagnostic imaging for prostate cancer. While this is a patent grant and not a regulatory rule, it may impact future research, development, and commercialization strategies for companies operating in the diagnostic imaging and pharmaceutical sectors, particularly those focused on PSMA-targeted therapies and diagnostics. Compliance officers in these sectors should be aware of this patent's existence and scope when assessing potential infringement risks or opportunities for licensing and collaboration.